In a world in which the probability of clinical success is just 10%-20% for new medicines, pharmaceutical multinationals increasingly turn to academia and biotech as a source of “de-risked” technology for their pipelines. This exchange of ideas, equity and capital depends on firm relationships between entities having apparently divergent interests: from not-for-profit research to international commerce.

As a former pharma contract negotiator, I spent much of my past life attempting to find common ground with university researchers and biotech leadership teams. In 2021, I had the privilege of returning to academia in the UK after a prolonged hiatus, and – more recently – of working with start-ups. In this blog, I will comment on some of the surprising trends I have observed in how pharma, biotech and academics balance the conduct of meaningful research with the requirements of their respective sectors. The views herein are entirely my own.